medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Number 07

<< Back Next >>

Ginecol Obstet Mex 2020; 88 (07)

Serous ovarian cancer. Report of 14 cases and review of the bibliography

González-Mariño MA

Language: Spanish
References: 41
Page: 442-449
PDF size: 222.98 Kb.


ABSTRACT

Objective: To describe the epidemiological, clinical, laboratory, surgical medical management and pathology characteristics in a series of 14 patients with serous ovarian carcinoma in a highly complex hospital and review of the literature in order to update the concepts.
Materials and Methods: Retrospective and descriptive case series study of a patient with serous ovarian cancer confirmed by pathology. The patients were studied in a highly complex general hospital between 2013 and 2016. Study variables: Epidemiological, clinical, laboratory surgical medical treatment, comorbidities, and pathology. Narrative review of the bibliography corresponding to information related to the evaluated variables.
Results: Fourteen women between the ages of 50 and 80 were diagnosed, 3 with a history of hysterectomy and 1 with tubal ligation. Histological diagnosis: 10 with high-grade serous tumor, 2 moderately differentiated, 1 low-grade serous and one not classified. Surgical procedures: hysterectomy, bilateral salpinges-oophorectomy, lymphadenectomy, omentectomy in 8 cases. They classified into states: IV in 6, 3 IIIB, 2 IC, 1 IIIC and 1 IB. Treatment 10 women with carboplatin and paclitaxel. Review 2227 articles were found, 41 sectioned.
Conclusions: Serous ovarian carcinoma is currently classified as low and high grade (more frequent and aggressive). This type was the most frequent, the risk factors found by the reduced number do not allow conclusions to be drawn.


REFERENCES

  1. González MA. Utilidad de los certificados de defunción en la evaluación de las causas de muerte por cáncer de ovario en Colombia durante el año 2008. MÉD.UIS.2014;27(2):9-14.

  2. Jelovac D, Armstrong D. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin.2011;61:183–203. doi: 10.3322/caac.20113

  3. Pratt J. Pathology of borderline and invasive cancers. Best Pract Res Clin Obstet Gynaecol. 2017; 41:15-30. doi: 10.1016/j.bpobgyn.2016.08.007.

  4. Hannibal CG, Vang R, Junge J, Kjaerbye-Thygesen A, Kurman RJ, Kjaer SK. A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006. Gynecol Oncol. 2012 Jun;125(3):655-60. doi: 10.1016/j.ygyno.2012.02.028

  5. Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High- Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. Int J Mol Sci. 2019 Feb 22;20(4). pii: E952. doi: 10.3390/ijms20040952.

  6. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014 Oct 11;384(9951):1376-88. doi: 10.1016/S0140-6736(13)62146-7.

  7. Köbel M, Reuss A, Bois A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010; 222: 191–198. doi: 10.1002/path.2744.

  8. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010; 221: 49–56. doi: 10.1002/path.2696.

  9. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019 Mar 23;393(10177):1240-1253. doi: 10.1016/S0140-6736(18)32552-2.

  10. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017; 41:3-14. doi: 10.1016/j.bpobgyn.2016.08.006.

  11. Sehouli J, Grabowski JP.Surgery for recurrent ovarian cancer: Options and limits. Best Pract Res Clin Obstet Gynaecol. 2017; 41:88-95. doi: 10.1016/j.bpobgyn.2016.10.009.

  12. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–49. doi: 10.3322/caac.20006

  13. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a populationbased study. doi: 10.1016/S1470-2045(13)70546-1.

  14. Assis J, Pereira C, Nogueira A, Pereira D, Carreira R, Medeiros R. Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis. Cancer Treat Rev. 2017 Dec; 61:35-52. doi: 10.1016/j. ctrv.2017.10.001.

  15. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006 Aug;108(2):361-368. doi: 10.1097/01.AOG.0000227787.24587.d1

  16. Salomon-Perzyński A, Salomon-Perzyńska M, Michalski B, Skrzypulec-Plinta V. High-grade serous ovarian cancer: the clone wars. Arch Gynecol Obstet. 2017 Mar;295(3):569- 576. doi: 10.1007/s00404-017-4292-1.

  17. Cooke SL, Brenton JD (2011) Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol 12(12):1169–1174. doi:10.1016/s1470-2045(11)70123-1

  18. Ducie J, Dao F, Considine M, Olvera N, Shaw PA, Kurman RJ, Shih IM, Soslow RA, Cope L, Levine DA. Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nat Commun. 2017 Oct 17;8(1):990. doi: 10.1038/s41467-017-01217-9.

  19. González MA. Costo efectividad de la cirugía reductora de riesgo en trompas y ovarios en casos con mutación del gen Brca1 en Colombia. Revista de Salud Pública 2018; 20(2)):232-236. doi: 10.15446/rsap.V20n2.64866.

  20. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967-975. doi: 10.1001/jama.2010.1237.

  21. Marchetti C, De Felice F, Palaia I, et al. Risk-reducing salpingooophorectomy:a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA1 and BRCA2 mutation carriers. BMC Womens Health. 2014;14:150. doi: 10.1186/s12905-014-0150-5.

  22. Trabert B1, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, et al; Ovarian Cancer Association Consortium. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst. 2014;106(2):djt431. doi: 10.1093/jnci/djt431.

  23. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2011, Issue 8. Art. No.: CD007565. DOI: 10.1002/14651858. CD007565.pub2.

  24. Sehouli J,Grabowski J.P. Surgery for recurrent ovarian cancer: Options and limits. Best Practice & Research Clinical Obstetrics and Gynaecology 2017;41: 88-95. doi: 10.1016/j. bpobgyn.2016.10.009

  25. Poole E.M., Konstantinopoulos P.A, Terry KL. Prognostic implications of reproductive and lifestyle factors in ovarian cancer. Gynecologic Oncology 2016;142 :574–587. doi: 10.1016/j.ygyno.2016.05.014

  26. Zhou Q, Hong L, Zuo M, He Z. Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4, 910 patients, Oncotarget 2017;8 (40)68938–68949. doi: 10.18632/oncotarget.20196

  27. Ethier JL,Desautels DN, Templeton AJ, Oza A, Amir E, Lheureux S. Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. Gynecol. Oncol. 2017;145:584– 594, https://doi.org/10.1016/j.ygyno.2017.02.026.

  28. Baert T, Van Camp J , Vanbrabant L, Busschaert P, Laenen A, Han S, Van Nieuwenhuysen E,Vergote I , Coosemans A. Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecologic Oncology 2018;150: 31–33. doi: 10.1016/j.ygyno.2018.05.004

  29. Wang Y, Liu P, Xu Y, Zhang W, Tong L, Guo Z, Ni H. Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer. Cancer Chemother Pharmacol. 2015; 75(2):255-62. doi: 10.1007/s00280-014-2622-6.

  30. Zhou M, Li L, Wang X ,Wang C, Wang D. Neutrophil-to- Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer. Cell Physiol Biochem 2018;46: 178-186. doi: 10.1159/000488420

  31. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al.Paraneoplastic Thrombocytosis in Ovarian Cancer. N Engl J Med. 2012;366(7):610–618. doi: 10.1056/NEJMoa1110352

  32. Allensworth SK, Langstraat CL, Martin JR, Lemens MA, McGree ME, Weaver AL, et al. Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer. Gynecol Oncol. 2013;130(3):499–504. doi: 10.1016/j.ygyno.2013.05.038

  33. Ma X, Wang Y, Sheng H, Tian W, Qi Z, Teng F, et al. Prognostic significance of thrombocytosis, platelet parameters and aggregation rates in epithelial ovarian cancer. J Obstet Gynaecol Res. 2014;40(1):178–183. doi: 10.1111/jog.12151

  34. Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival – a review of the epidemiological literature. J Ovarian Res. 2009;2:13. doi: 10.1186/1757-2215-2-13

  35. Felder M, Kapur A, Gonzalez-Bosquet J, Horibata S, Heintz J, Albrecht R, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer 2014; 13:129. doi: 10.1186/1476-4598-13-129

  36. Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, et al. The prognostic value of pretreatment of CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 2009; 115:1028–1035. doi: 10.1002/cncr.24084

  37. Morales-Vásquez F, Pedernera E, Reynaga-Obregón J, López-Basave HN, Gómora MJ, Carlón E, Cárdenas S, Silva- Ayala R, Almaraz M, Méndez C. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma. Journal of Ovarian Research 2016: 9:41 doi 10.1186/s13048-016-0247-6.

  38. Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, et al, and the participants of the 5th Ovarian Cancer Consensus Conference. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup:first-line interventions. Ann Oncol 2017; 28: 711–717. doi: 10.1093/ annonc/mdx011

  39. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473–2483. doi: 10.1056/NEJMoa1104390

  40. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade- Lauraine E, Kristensen G et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484–2496. doi: 10.1056/NEJMoa1103799

  41. Ripamonti CI, Easson AM, Gerdes H. Management of malignant bowel obstruction. Eur J Cancer 2008; 44: 1105–1015. doi: 10.1016/j.ejca.2008.02.028




2020     |     www.medigraphic.com